文献速递生殖医学

精子氨肽酶N可识别卵母细胞捐赠周期中高质量囊胚与可用胚胎的潜力

Sperm aminopeptidase N identifies the potential for high-quality blastocysts and viable embryos in oocyte-donation cycles.
PubMed 文献 · Hum Reprod · 2022-01-01

本研究纳入西班牙Clínica IVI Bilbao在2014年9月至2015年7月间接受卵母细胞捐赠周期的81对夫妇,共获得611枚胚胎,用定量与半定量流式细胞术检测精子氨肽酶N(APN)水平,并按西班牙生殖生物学研究协会(ASEBIR)标准评估胚胎质量。结果显示精子APN水平低的精液样本产生更多扩张、孵化和可用囊胚,较少早期、停滞和不可用囊胚;作者认为精子APN有可能成为识别高质量胚胎潜力与诊断男性不育的新分子生物标志物。

要点

  • 精子APN水平低的精液样本产生更多扩张、孵化和可用囊胚,早期、停滞和不可用囊胚更少。
  • 低APN精液样本用于ICSI时,第5天获得发育良好囊胚的累积概率增加1.38倍,第6天增加1.90倍。
  • 低APN精液样本用于ICSI时,获得可用胚胎的可能性增加1.48倍。

核心结论

  • 人类精子APN有可能成为识别高质量和可用胚胎潜力的新分子生物标志物。

研究设计与样本

  • 研究纳入2014年9月至2015年7月在西班牙Clínica IVI Bilbao接受卵母细胞捐赠周期的81对夫妇,共获得611枚胚胎。
  • 研究在辅助生殖单位和学术研究实验室进行,精液样本按世界卫生组织指南检查分类。
  • 精子采用不连续胶体二氧化硅梯度(45-90%)技术从精液中分离,胚胎质量与发育按西班牙生殖生物学研究协会(ASEBIR)标准判定。
  • 人类精子APN水平采用定量和半定量流式细胞术分析。

主要发现

  • 发育最好和可用的囊胚与低精子APN水平相关。
  • APN水平较低的精液样本产生更多扩张、孵化和可用囊胚,早期、停滞和不可用囊胚更少。
  • 采用低APN水平精液样本行ICSI时,第5天获得发育良好囊胚的累积概率增加1.38倍,第6天增加1.90倍。
  • 采用低APN水平精液样本行ICSI时,获得可用胚胎的可能性增加1.48倍。

临床怎么用

  • 作者认为人类精子APN有潜力成为帮助识别高质量胚胎潜力和诊断男性不育的新分子生物标志物,尤其当精液参数接近阈值时。
  • 作者认为对于可用囊胚数量对ART成功至关重要的夫妇,它可能是一个关键工具。

局限性

  • 数据来自单一生育诊所。
  • 需要多中心研究来证实结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is there a relationship between human sperm aminopeptidase N (APN) and embryo development in humans? SUMMARY ANSWER: Human sperm APN could possibly become a new molecular biomarker for identifying the potential for high-quality and usable embryos. WHAT IS KNOWN ALREADY: The diagnosis of male fertility is one of the major concerns of reproductive medicine. Approximately 30-40% of men with otherwise normal fertility parameters are still unable to achieve pregnancy. The predictive clinical value of semen analysis to identify fertile or infertile males is limited; therefore, new diagnostic methodologies for sperm are urgently required. Sperm APN may be a relevant molecular marker due to its high concentration in sperm cells and its important roles in sperm physiology, such as its functions in motility, acrosome reaction and embryo development. STUDY DESIGN, SIZE, DURATION: This study included 81 couples who underwent oocyte-donation cycles at Clínica IVI Bilbao (Spain), yielding 611 embryos, between September 2014 and July 2015. PARTICIPANTS/MATERIALS, SETTING, METHODS: This study was conducted in an assisted reproduction unit and an academic research laboratory. All the semen samples were examined and classified following World Health Organization guidelines. Spermatozoa were isolated from semen using the discontinuous colloidal silica gradient (45-90%) technique. Embryo quality and development were determined according to the Spanish Association of Reproduction Biology Studies (ASEBIR) criteria. Human sperm APN levels were analyzed by quantitative and semiquantitative flow cytometry. MAIN RESULTS AND THE ROLE OF CHANCE: The most well-developed and usable blastocysts were associated with low sperm APN levels. Semen samples that had lower APN levels generated more expanded, hatched and usable blastocysts and fewer early, arrested and non-usable blastocysts. The cumulative probability of having well-developed blastocysts increased by 1.38-fold at Day 5 and 1.90-fold at Day 6 of embryo development, and the likelihood of having usable embryos increased by 1.48-fold, when semen samples with low APN levels were used during the ICSI technique. LIMITATIONS, REASONS FOR CAUTION: The data were obtained from a single fertility clinic. A multicentre study will be required to confirm the results. WIDER IMPLICATIONS OF THE FINDINGS: Human sperm APN has the potential to become a new molecular biomarker to help identify the potential for high-quality embryos and diagnose male infertility, especially when seminal parameters are close to the threshold values. It could be a crucial tool for couples for whom the number of usable blastocysts is critical for ART success. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by grants from the Basque Government (GIC15/165) and the University of the Basque Country (UPV/EHU) (EHUA14/17). The authors declare that they have no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Gianzo M, Urizar-Arenaza I, Muñoa-Hoyos I, et al. Sperm aminopeptidase N identifies the potential for high-quality blastocysts and viable embryos in oocyte-donation cycles. Hum Reprod. 2022. PMID: 35984316. doi:10.1093/humrep/deac170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。